Introduction
============

Mature circulating endothelial cells (CEC) were first described in 1970 [@B1],[@B2] and have been recognized as markers of vascular injury [@B3]. CEC can be derived from the vascular wall (mature CEC), or recruited from the bone marrow, as endothelial progenitor cells (EPC) [@B4], in response to various stimuli such as ischemia, vascular trauma [@B5], acute myocardial infarction [@B6], sickle cell anemia [@B7], vasculitis [@B8], and pulmonary hypertension [@B9]. The presence of these cells has also been associated with angiogenic potential [@B10].

CEC and EPC are extremely rare events in peripheral blood, where they represent between 0.01% and 0.0001% of mononuclear cells [@B10],[@B11]. Despite the lack of a clear consensus on their phenotypic definition, CEC are generally identified as cells expressing endothelial markers (CD 146, CD 144, vWF, VEGFR-2) in the absence of hematopoietic (CD 45, CD 14) and progenitor (CD 34, CD 133) markers [@B8],[@B10],[@B12],[@B13]. Similarly EPC are defined by the presence of at least one marker of immaturity and one marker of the endothelial lineage [@B14]-[@B16]. However, although many different panels have been proposed to characterize EPC, no consensus has been reached about their precise phenotype.

The pathogenesis of deep vein thrombosis (DVT) involves alterations of blood flow, blood components and endothelial injury. Previous studies have shown that cells derived from the bone marrow can be identified within a venous thrombus 7 and 14 days after partial ligation of the inferior vena cava in mice, and that CEC counts increase after thrombus induction [@B17]. However, to our knowledge, no study investigated the presence of CEC in with DVT in the clinical setting. Therefore, the aim of our study was to investigate the presence of CEC and EPC after DVT in humans in different time-points of their disease course, and to correlate our findings with the time-course of CEC and EPC detection in an experimental model of DVT in mice.

Methods
=======

Patients with DVT
-----------------

Patients with DVT at diagnosis (acute DVT), between 18 and 60 years of age, were recruited from 3 hospitals in Campinas, SP, Brazil. Samples were collected between December 2007 and May 2008. The diagnosis of DVT was confirmed by Doppler ultrasonography. Patients in whom DVT was associated with endothelial injury, such as trauma, cancer, antiphospholipid antibodies, surgery within the last 3 months, pregnancy, renal or hepatic disease were excluded from the study. The pre-existing conditions presented by patients with acute DVT were: Factor V Leiden mutation in one patient and oral contraceptive use in two patients. In addition, 3 patients presented hypertension, 2 presented diabetes and 1 presented obesity.

A second group of patients (chronic DVT) was composed by individuals 1-3 years after withdrawal of warfarin therapy, which were recruited from the Outpatient Clinic of Hemocentro de Campinas / UNICAMP, between February and September 2009. In this group of patients, two presented the Factor V Leiden mutation, and two were using oral contraceptives at the moment of DVT. In addition, 3 presented hypertension, 2 presented diabetes and 1 was obese.

In order to minimize the environmental interference, the control group was composed by healthy individuals who lived at the same geographic region of the patients, matched by age and gender. Individuals with a personal or familial history of DVT before the age of 50 years-old were not included as controls.

The clinical and demographic characteristics of all the individuals included in this study are shown in Table [1](#T1){ref-type="table"}.

Whole blood (10mL) samples were collected from all individuals into EDTA-containing tubes. In addition, a second sample was obtained from patients from the acute DVT group between 9-15 months after the diagnosis (follow-up). A complete blood count was performed immediately after sample collection on Cell Dyn 1700^®^ (Abott Laboratories, North Chicago, IL, USA).

The study was approved by the Local Ethics Committee and all the individuals signed a written informed consent. All the procedures utilized in this study were in agreement with the Declaration of Helsinki.

FeCl~3~-induced vein thrombosis model in mice
---------------------------------------------

Vein thrombosis was induced in 8-weeks old C57Bl/6 male mice with FeCl~3~, according to a previously described method [@B18]. Briefly, after intramuscular anesthesia with ketamine (100mg/kg) and xylazine (20mg/kg), the inferior vena cava (IVC) was exposed by blunt dissection between the renal and the iliolumbar veins. A piece of filter paper (3mm x 1mm) presaturated with a 15% FeCl~3~ solution was placed over the IVC for 30 seconds. IVC occlusion by the thrombus was confirmed using a perivascular flow probe (Model 0.5 PB, Transonic Systems, Ithaca, NY, USA). The incisions were closed after the procedures, and the animals were monitored for specific time-points (15, 30 and 45 minutes; 1, 24, 48 and 72 hours; n=5-8 animals per time-point), at which the abdominal was re-opened, and blood and histological samples were collected. During these periods, the animals were treated with analgesic if they presented signs of pain. At each time-point, 800 µL of blood was collected by cardiac puncture in EDTA and immediately processed. In addition, a 10-mm sample of the IVC containing the thrombus and the abdominal aorta was cut out and embedded in OCT compound. Next, transverse 10 μm frozen sections were obtained at 100 μm intervals. Verhoff van Gienson staining was applied in order to measure the size of IVC lumen and to estimate its occupation by the vein thrombus. The total thrombus area was calculated using ImageJ software^®^ (U. S. National Institutes of Health, Bethesda, MD, USA).

CEC and EPC were analyzed inside the thrombus by immunofluorescence, based on a previously described protocol [@B10]. Briefly, samples were fixed with acetone at 4ºC for 20 minutes and washed for 5 minutes with PBS. After that, samples were incubated with boiling and cold 10mM of sodium citrate (pH=6) solutions, for 30 minutes each. After washing with PBS for 5 minutes, blockage was performed for 20 minutes with 0.05% PBS/BSA. The primary antibodies were diluted with PBS/BSA 0.05% and incubated at 37ºC for 1 hour, or overnight at 4ºC. Finally, anti-rat secondary antibodies conjugated with FITC (cat. 81-9511, Invitrogen, Carlsbad, US), Cy5 (cat. 81-9516, Invitrogen) and DAPI were used. CEC were identified by the positivity for CD 31, whereas EPC were identified by the positivity for CD 34 and Sca1.

For the histochemical staining, slides were fixed in acetone at 4°C for 20 minutes, and incubated in a 5% hematoxylin, 29% FeCl~3~, Weigerts solution and deionized water at 25°C for 10 minutes. Next, slides were incubated with 2% FeCl~3~, washed in 95% ethanol and water, stained with Van Gienson solution and dehydrated.

All animal experiments were approved by the University Committee of Ethics in Animal Experimentation (protocol 2121-1).

Monoclonal antibodies
---------------------

The following antibodies were used in immunohistochemistry studies: CD 31 monoclonal antibody (clone 390, Caltag-Medsystems Ltda., Buckingham, UK), CD 34 (clone RAM34, eBioscience, San Diego, USA) and Sca1 (clone D7, Becton Dickinson, Sparks, USA). Antibodies used for flow cytometry are listed in table [2](#T2){ref-type="table"}.

Quantification of CEC and EPC in humans and mice
------------------------------------------------

In humans, leukocyte counts were adjusted to 5 - 10 x 10^3^/μL on blood samples. Blood (100 µL) and the previously titrated monoclonal antibodies (5 µL) were incubated for 20 minutes at 4°C in the dark. After the incubation, erythrocytes were lysed with 2 mL of 1:10 diluted FACS *lysing buffer* (Becton Dickinson) and incubated again for 10 minutes. The remaining leukocytes were washed with 2 mL 2% PBS/BSA (pH=7.4) and the tubes were centrifuged 500 g for 5 minutes and finally resuspended in 500 μL of wash buffer. The acquisition was performed by a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed by Cell-Quest and Paint-a-Gate softwares (BD, Bioscences).

In humans, CEC and EPC were defined according to Khan and colleagues [@B10], and the classification is summarized in Table [3](#T3){ref-type="table"}. CEC were defined as positive events to CD 31, CD 144, CD 146 and negative to CD 45 and CD 133. As CD 34 may be positive or negative [@B4],[@B19],[@B20] EPC were defined as positive events to CD 34, CD 133, CD 144, CD 146, VEGFR-2, and negative to CD 34, CD 45 and CD 31. Figure [1](#F1){ref-type="fig"} represents some flow cytometry steps during the CEC and EPC analyses, where the selected populations are shown in red. Initially, the background was removed by the analyses of isotype control antibodies. The debris were excluded on the FSC/SSC plot (Figure [1](#F1){ref-type="fig"}A), and so were leukocytes on CD 45/SSC plot (Figure [1](#F1){ref-type="fig"}B). The CEC were gated on CD 31/CD 45, CD 144/CD 45 and CD 146/CD 45 plots (Figure [1](#F1){ref-type="fig"}C). The analysis for EPC was similar, observing the positivity for CD 133. Then, a gate was drawn in the CD45^-/dim^, CD144^+^ (CD146 or VEGFR-2) and CD31^+^plots. EPC were classified into CD133^+^ and/or CD34^+^ (Figure [1](#F1){ref-type="fig"}D).

In mice, CEC were defined as positive cells to VEGFR-2 and negative to Sca1 and CD 45 [@B21]. EPC were defined as positive events to CD 34, VEGFR-2, Sca1 and negative to CD 45.

Due the multiplicity of antibodies available to the CEC and EPC analyses, and the lack of consensus about the best choice to their characterization, alternative panels were also applied in an attempt to confirm the CEC and EPC data in the analyses. In humans and mice, CEC were also analyzed as positive events to CD 31, CD 34 and VEGFR-2, and negative to CD 45, and the EPC were analyzed as positive events to CD 34 and VEGFR-2 and negative to CD 45 and CD 31.

During standardization, 300.000 cells were acquired and the percentage of CEC and EPC were very similar to results obtained during acquisition of 50,000 and 100,000 cells in mice and humans samples, respectively. So, these lower counts were subsequently used. In animals, the results of CEC and EPC were expressed as percentage, since the blood volume was not sufficient to perform all analyses and leukocyte counting. In humans, the percentage of CEC and EPC were calculated separately, by multiplying the percentage of positive events to the number of leukocytes/μL and dividing the result per 100.

Statistical Analysis
--------------------

Data are presented as means ± SEM, or as medians and ranges. Fisher or chi-square tests were applied to compare categorical variables, and Mann-Whitney test was used to compare continuous variables. For comparison of paired variables, the Wilcoxon test was applied. Analyses were performed using the R Development Core Team 2010 software (Vienna, Austria), and the P \< 0.05 values were considered statistically significant.

Results
=======

CEC and EPC in patients with DVT
--------------------------------

The number of CEC was significantly higher 24-72 hours after the DVT episode \[5.0 (0.3 - 45.0)\] when compared to healthy individuals \[0.1 (0 - 0.3); p \<0.001\] and to chronic patients \[0.2 (0.1 - 0.5); p = 0.04\] (Figure [2](#F2){ref-type="fig"}). In addition, CEC count was significantly higher at diagnosis when compared to the follow-up collection after 9-15 months in four of the five patients for whom serial samples were available \[0.4 (0 - 0.7); p = 0.03\] (Figure [3](#F3){ref-type="fig"}). EPC were consistently absent during the entire experiments, despite the use of several markers.

Time-course of CEC release in a mouse model of DVT
--------------------------------------------------

Thrombus formation was observed in all mice. The Verhoff van Gienson coloration allowed the observation of the vein thrombus inside the IVC (15, 30 and 45 minutes; 1, 24, 48 and 72 hours (Figure [4](#F4){ref-type="fig"}). Total occlusion occurred between 15 minutes and 1 hour. After that, the IVC showed a partial occlusion, decreasing from from 85.4% after 24h to 65.3% after 48h, and to 51.1% after 72h. Signs of recanalization could be observed by histological analyses, 24 hours after DVT induction. The analysis of the total area of the thrombus showed a decrease from 100% after 1 hour to 80.35 ± 4.27 % at 24h; 63.50 ± 5.06 % at 48h and 54.95 ± 3.44 % at 72h (n=4 per time-point).

The immunofluorescence staining did not show endothelial (CD 31^+^) and progenitor cells (CD 34^+^/Sca1^+^) inside and on the periphery of the vein thrombus. Endothelial cells could be visualized on the endothelial surface of the abdominal aorta and on the arterioles, after 1 hour (n = 5-8 animals per time-point; data not shown).

The percentage of CECs and EPCs in experimental DVT are shown in Figure [5](#F5){ref-type="fig"} as determined by FACS analysis. CEC counts were significantly higher 24 hours after DVT induction \[0.01 (0.006 - 0.03)\] in comparison to baseline \[0.004 (0.002 - 0.02); P = 0.03\], reaching peak values 48 hours after DVT \[0.115 (0.01 - 0.87); P = 0.001\], and decreasing substantially after 72 hours \[0.007 (0 - 0.04); P = 0.03\]. EPC presented a similar behavior to CEC, with higher counts 24, 48 and 72h after DVT. However, at the 24 and 72h time-points, counts were slightly higher in comparison to CEC levels at similar time-points. When data were analyzed using the alternative panels, CEC and EPC results were similar to those obtained on the standard panels, except for the fact that EPC peaked 48h after DVT induction, and remained significantly higher until the 72 hour time-point (data not shown).

Discussion
==========

Hypercoagulability, alterations in blood flow and endothelial injury/dysfunction have been recognized as key elements on the pathogenesis of DVT since 1856 [@B22]. Among these elements, endothelial alterations are probably the less studied due do intrinsic difficulties of such investigation. Endothelial cells produce prostacyclin and nitric oxide, which show anti-thrombotic effects by increasing platelet cellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) [@B23]. It has also been suggested that EPC participate in the processes of post-natal angiogenesis [@B24]-[@B27]. Accordingly, despite difficulties in the characterization of these cells, it is possible to speculate that CEC and EPC participate in processes such as vessel recanalization and repair after DVT.

Prior studies in animal models of normal or induced vascular growth after injury suggest that proliferating clusters of endothelial cells are apparent in vessels without signs of vascular denudation, supporting the theory of endogenous endothelial replacement [@B28]-[@B30]. Moreover, Rafii and collegues [@B31] suggested that if large areas of endothelium are removed and/or damaged, greater influx of circulating cells ensues as a first response to injury. In this instance, a host of circulating hematopoietic cells, along with platelets, would readily attach to damaged areas. Accordingly, these cells could also play a role on reparative events following the DVT. So, to gain further knowledge about the participation of CEC and EPC in venous thromboembolism, we evaluated their presence in several phases after DVT in humans and also explored the time-course of CEC and EPC release in a mouse model of DVT.

The total occlusion of the lumen of mice IVC by the thrombus, between 15 minutes and 1 hour, occurred as previously described [@B18]. The total thrombus area decreased after 1 hour, and continued to do so until the last time-point (72h), indicating the occurrence of recanalization. The presence of the CEC and EPC on regions where the flow were reestablished after 1 hour suggest a role for these cells at some part of this process. Li and coworkers [@B32] observed a substantial increase in VEGF, angiopoietin-1 and monocyte chemotactic protein-1 (MCP-1) levels by real-time PCR and Western blotting, when bone marrow-derived EPCs were transplanted into a rat model of venous thrombosis. These microenvironment changes culminated in thrombi organization and recanalization, but it remains speculative if these changes were part of the reparative processes or only biomarkers of endothelial injury.

In our animal analyses, EPC counts were higher in comparison to CEC at 24 and 72 hours. The persistence of EPC elevation, even after CEC counts returned to the baseline could indicate a more active participation of EPC in the response to injury after DVT, and a more passive role of CEC. In acute myocardial infarction (MI), the number of circulating EPCs was markedly increased from the early phase of the disease, with peak values on day 7, that returned to baseline within 60 days [@B33]. In addition, plasma VEGF levels were closely related to circulating EPC numbers. In addition, the active participation of EPC in regenerative processes has been demonstrated during revascularization in response to tissue ischemia [@B34].

To our knowledge, CEC and EPC have not been previously evaluated in humans in the context of venous thromboembolism. In this study, both groups of DVT patients presented higher CEC counts in comparison to healthy individuals, and the acute DVT group showed higher counts than chronic DVT patients. These results are in accordance with our results obtained in the animal model. Our results do not define whether CECs are associated with vessel injury and repair, or represent a biomarker of inflammation associated with DVT. Results obtained in the chronic DVT group suggest that inflammation is at least in part associated with increased CEC counts in the context of DVT. In the future, similar studies in patients with post-thrombotic syndrome, in which the process of vessel repair is no longer active, could further clarify this issue.

As on previous studies, the EPCs were extremely rare in our patients. The literature has shown an inverse correlation between the number of EPCs and presence of atherosclerosis and cardiovascular dysfunction in human subjects [@B35]-[@B37]. However, it has also been speculated that the studies with EPC might not really reflect the number of these cell in the circulation, due to difficulties in characterizing these cells [@B10].

Studies with CEC and EPC are always complicated by the lack of consensus regarding the surface markers that identify these [@B38]-[@B40]. As Timmermans and coworkers [@B41] appropriately pointed, if an EPC is defined as an immature precursor cell that displays postnatal vasculogenic activity, they should be capable for forming new CECs and blood vessels *in vivo.*However, this definition has often yielded conflicting results and created obstacles to the direct comparison of data. Nevertheless, several investigators have suggested that haematopoietic-derived cells may contribute to vascular [@B42]-[@B44].

Despite this lack of consensus, and the fact that antigen expression may be variable on endothelial cells, and that other cell lines with overlapping phenotypes have been described, we obtained similar results in mice and in DVT patients, supporting the biological relevance of our data, as well as the definition of CEC and EPC used in this study. Moreover, in order to minimize the impact of these potential biases, all analyses of this study were performed using a co-called alternative panel for both CEC and EPC, with which similar results were obtained.

Our study has several limitations. The most important one is the already mentioned difficulty in characterizing CEC and EPC. We tried to minimize this by confirming our results with an alternative panel. In addition, the fact that we obtained similar results in humans and mice strengthens our results. Second, the use of beads to isolate CEC and EPC could have strengthened our results. Third, the number of patients included in this study is relatively small to make definitive conclusions. However, our idea was to perform a pilot and exploratory study comparing results obtained in humans with those obtained in animal models. We do not intend by any means to suggest that CEC and EPC should be considered biomarkers of DVT, or that our data define the roles of these cells in DVT.

In conclusion, we demonstrated an increase in CEC count in humans after an acute episode of DVT. We also demonstrated that these cell counts remain significantly elevated at later time-points (chronic DVT and acute DVT at follow-up), when compared to healthy individuals. Overall, these trends were confirmed in a more controlled model of experimental DVT in mice, in which both CEC and EPC counts were increased after DVT induction peaking 48 hours after the acute event. Together, these data suggest that EPC and CEC might have a role in the early and late phases of vessel repair in the context of DVT, as mentioned in other conditions associated with endothelial injury. However, the precise role of these cells in these processes, whether as active players in vessel repair, or as mere biomarkers of endothelial injury, remains to be determined.
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![Flow cytometry analyses, showing (A) distribution by forward-scatter (FSC) *vs* side-scatter (SSC); (B) CD 45 *vs* SSC (red); (C) EPC population (CD 144 *vs* FSC) and (D) CEC population (CD 144 *vs* CD 133). Debris were excluded on the FSC/SSC plot (A), as were leukocytes on CD 45/SSC plot (B). The CEC were gated on CD 31/CD 45, CD 144/CD 45 and CD 146/CD 45 plots (C). The analysis for EPC was similar, observing the positivity for CD 133. A gate was then drawn in the CD45^-/dim^, CD144^+^ (CD146 or VEGFR-2) and CD31^+^plots. EPC were classified into CD133^+^ and/or CD34^+^ (D).](ijmsv10p1746g001){#F1}

![CEC counts in DVT patients at specific time-points, as on acute DVT (24-72 hours after the episode) and on chronic DVT patients). A significant elevation of CEC counts can be observed in six of nine patients, both at immediate and late time-points after DVT compared to healthy controls.](ijmsv10p1746g002){#F2}

![CEC counts in patients at specific time-points: on acute DVT (24-72 hours after the episode) and on the follow-up (9-15 months after the diagnosis). A significant increase in CEC (CD 31^+^ CD 146^+^ CD 45^-^ CD 133^-^) counts was observed at immediate DVT in comparison to the late episode (P = 0.03; Willcoxon test).](ijmsv10p1746g003){#F3}

![Representative microphotographs of vein thrombosis in mice inferior vena cava, several time-points after thrombosis induction with FeCl~3~ (n = 5-8 animals per time-point). (A) Baseline, (B) 15 minutes, (C) 30 minutes, (D) 45 minutes, (E) 1 hour, (F) 24 hours, (G) 48 hours, (H) 72 hours. Color arrows indicate the inferior vena cava (yellow arrow), the thrombi (red arrows) and the descending aorta artery (blue arrows).](ijmsv10p1746g004){#F4}

![CEC and EPC counts in experimental DVT at different time-points. (A) CEC showed a significant elevation 24 hours after DVT induction, with peak counts after 48 hours. After 72 hours, CEC counts decreased sharply. (B) EPC showed significant elevation at 24 hours, peaking after 48 hours after DVT induction. EPC counts also decreased at 72 hours, less sharply than CEC. \**P*\<0.05, Mann-Whitney test.](ijmsv10p1746g005){#F5}

###### 

Clinical and demographic data from patients with deep vein thrombosis (DVT) and controls

                                                      Control (n = 11)   Acute DVT (n = 9)   Chronic DVT (n = 11)   P
  --------------------------------------------------- ------------------ ------------------- ---------------------- ---------
  Age\* (years)                                       29 (21 - 52)       45 (26 - 54)        44 (28 - 56)           0.5\*\*
  Time between DVT and sample collection\* (months)   \-                 \-                  10.5 (4 - 36)          \-
  Gender (female:male)                                9:2                7:2                 6:4                    0.4†
  DVT site (distal:proximal)                          \-                 1:8                 6:4                    0.06†
  Use of OC                                           1 (9.0%)           2 (22.2%)           2 (18.2%)              0.1†
  Previous history of DVT                             0                  1 (11.1%)           1 (9.0%)               0.5†

OC (oral contraceptives); \* Median (range); \*\* Mann-Whitney test; † Fisher\'s exact test.

###### 

List of antibodies used in flow cytometry studies.

  Antigen   Species   Clone               Fluorochrome\*   Manufacturer
  --------- --------- ------------------- ---------------- -------------------
  CD31      Human     MBC78.2; PECAM1.2   FITC             Invitrogen
  CD31      Mouse     390                 FITC             Caltag-Medsystems
  CD34      Human     8G12                FITC             BD
  CD34      Mouse     RAM34               FITC             eBioscience
  CD45      Human     2D1                 PerCP            BD
  CD45      Mouse     30-F11              PerCP            BD
  CD133     Human     AC133               APC              Miltenyi
  CD144     Human     TEA1/31             PE               Beckman Coulter
  CD146     Human     P1H12               PE               BD
  VEGFR-2   Human     89106               PE               R&D
  VEGFR-2   Mouse     AVAS 12α1           PE               BD
  Sca1      Mouse     D7                  FITC             BD
  IgGs      Human     \-                  FITC             Dako
  PE                                                       
  PerCP                                                    
  APC                                                      

\* FITC: Fluorescein isothiocyanate , PE: Phycoerthrin; PerCP: Peridinim chlorophyll, APC: Allophycocyanin.

###### 

Characterization of CEC and EPC in mice and humans by flow cytometry.

            Mice      Mice (alternative panel)   Humans    Humans (alternative panel)                                           
  --------- --------- -------------------------- --------- ---------------------------- ------------ --------- --------- ------ --
  **CEC**   VEGFR-2   CD45                       CD31      CD45                         CD31         CD45      CD31      CD45   
                      Sca1                       CD34                                   CD144        CD133     CD34             
                      VEGFR-2                              CD146                        CD34 (sub)   VEGFR-2                    
                                                           CD34                                                                 
  **EPC**   CD34      CD45                       CD34      CD45                         CD34         CD45      CD34      CD45   
            VEGFR-2                              VEGFR-2   CD31                         CD133        CD31      VEGFR-2   CD31   
  Sca1                                                     CD144                                                                
                                                           CD146                                                                
                                                           VEGFR-2                                                              
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